TUMOR, SOLID
Clinical trials for TUMOR, SOLID explained in plain language.
Never miss a new study
Get alerted when new TUMOR, SOLID trials appear
Sign up with your email to follow new studies for TUMOR, SOLID, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cancer drug trial tests immune system activation
Disease control CompletedThis early-stage study tested the safety and best dose of a new experimental drug called BDB001, which aims to activate the immune system to fight cancer. It was tested both alone and in combination with an existing immunotherapy drug (pembrolizumab) in 87 adults with advanced so…
Matched conditions: TUMOR, SOLID
Phase: PHASE1 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Precision proton beams target tumors in new device trial
Disease control CompletedThis trial tested a new proton therapy machine called the Varian ProBeam System. It involved 47 patients with various solid tumors to see how well the machine controlled their cancer and how safe it was. The main goal was to collect data to support the device's approval for medic…
Matched conditions: TUMOR, SOLID
Phase: NA • Sponsor: Varian, a Siemens Healthineers Company • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Sound waves zap kidney tumors in new medical trial
Disease control CompletedThis trial tested a new, non-invasive device that uses focused sound waves to destroy small kidney tumors. The study involved 20 adults with tumors 3cm or smaller to see if the treatment could completely cover the tumor and was safe. Patients were followed for six months after th…
Matched conditions: TUMOR, SOLID
Phase: NA • Sponsor: HistoSonics, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New Immune-Boosting drug combo tested in advanced cancer patients
Disease control CompletedThis early-stage study tested the safety of an experimental immune-boosting drug called BDB001, given alone and combined with the immunotherapy drug atezolizumab (Tecentriq). It involved 40 adults with advanced solid tumors that had stopped responding to standard treatments. The …
Matched conditions: TUMOR, SOLID
Phase: PHASE1 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New drug trial targets tough cancers that resist standard immunotherapy
Disease control CompletedThis study tested an experimental immunotherapy drug called BDB001 for people with advanced solid tumors that had stopped responding to standard immune checkpoint inhibitor treatments. The trial aimed to see if BDB001 could help control cancer growth and was safe for patients. It…
Matched conditions: TUMOR, SOLID
Phase: PHASE2 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New Immune-Boosting drug enters human testing for tough cancers
Disease control CompletedThis early-stage study tested a new drug called BDB001, which aims to activate the immune system to fight cancer. It was given to people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the drug's safety and find the righ…
Matched conditions: TUMOR, SOLID
Phase: PHASE1 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New combo therapy targets Hard-to-Treat cancers
Disease control CompletedThis study tested whether a combination of two immunotherapy drugs (durvalumab and tremelimumab) could slow the growth of recurrent solid tumors that have a high number of genetic mutations. It involved 14 adult patients whose cancer had returned or stopped responding to prior tr…
Matched conditions: TUMOR, SOLID
Phase: PHASE2 • Sponsor: John L. Villano, MD, PhD • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Advanced proton therapy tested on multiple cancer types
Disease control CompletedThis study tested a new proton therapy system for treating various solid tumors in 47 patients. The goal was to evaluate how well the system controls tumors and how safe it is for patients. Researchers followed patients for 3 months after treatment to measure tumor response and t…
Matched conditions: TUMOR, SOLID
Phase: NA • Sponsor: Varian, a Siemens Healthineers Company • Aim: Disease control
Last updated Mar 18, 2026 14:40 UTC
-
New immune therapy drug enters human testing for tough cancers
Disease control CompletedThis first-in-human study tested a new experimental drug called HMBD-002, which targets a protein on cancer cells called VISTA. The trial aimed to find a safe dose and schedule for giving HMBD-002 alone and combined with the approved immunotherapy drug pembrolizumab (Keytruda®) i…
Matched conditions: TUMOR, SOLID
Phase: PHASE1 • Sponsor: Hummingbird Bioscience • Aim: Disease control
Last updated Mar 11, 2026 14:53 UTC